The differential effect of cyclosporine on hypnotic response and pain reaction in mice

Anesthesia and Analgesia

Volumn 105, Issue 5, 2007, Pages 1489-1493

  Sato, Yuki ^a   Onaka, Tatsushi ^a   Kobayashi, Eiji ^a   Seo, Norimasa ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; KETAMINE; MULTIDRUG RESISTANCE PROTEIN 1; PENTOBARBITAL;

ANIMAL BEHAVIOR; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; HYPERALGESIA; HYPNOSIS; KNOCKOUT MOUSE; MALE; MOTOR PERFORMANCE; MOUSE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RIGHTING REFLEX; STATISTICAL SIGNIFICANCE; TAIL FLICK TEST; WILD TYPE;

EID: 37349018641     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000286173.60987.72     Document Type: Article

References (35)

1. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38
2. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 1991;352:803-7
3. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A. J Clin Invest 1995;96:1698-705
4. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24
5. Lucas VP, Ponge TD, Plougastel-Lucas ML, Glemain P, Hourmant M, Soulillou JP. Musculoskeletal pain in renal-transplant recipients. N Engl J Med 1991;325:1449-50
6. Grotz WH, Breitenfeldt MK, Braune SW, Allmann KH, Krause TM, Rump JA, Schollmeyer PJ. Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation. Transpl Int 2001;14:16-23
7. Kida A, Ohashi K, Kobayashii T, Sakai M, Yamashita T, Akiyama H, Kishida S, Sakamaki H. Incapacitating lower limb pain syndrome in cord blood stem cell transplant recipients with calcineurin inhibitor. Pathol Oncol Res 2004;10:204-6
8. Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int 2006;70:1367-70
9. Adams DH, Ponsford S, Gunson B, Boon A, Honigsberger L, Williams A, Buckels J, Elias E, McMaster P. Neurological complications following liver transplantation. Lancet 1987;1:949-51
10. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987;317:861-6
11. Kunzendorf U, Brockmoller J, Jochimsen F, Keller F, Walz G, Offermann G. Cyclosporine metabolites and central-nervous-system toxicity. Lancet 1988;1:1223
12. Hughes RL. Cyclosporine-related central nervous system toxicity in cardiac transplantation. N Engl J Med 1990;323:420-1
13. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500
14. Cirella VN, Pantuck CB, Lee YJ, Pantuck EJ. Effects of cyclosporine on anesthetic action. Anesth Analg 1987;66:703-6
15. Hoffman A, Levy G. Kinetics of drug action in disease states. XXXVI: Effect of cyclosporine on the pharmacodynamics and pharmacokinetics of a barbiturate (heptabarbital) in rats. J Pharm Sci 1990;79:19-22
16. Hoffman A, Habib G, Gilhar D, Zohar H. Cyclosporine increases the CNS sensitivity to the hypnotic effect of phenobarbitone but not ethanol in rats. J Pharm Pharmacol 1994;46:760-4
17. Niemann CU, Stabernack C, Serkova N, Jacobsen W, Christians U, Eger EI II. Cyclosporine can increase isoflurane MAC. Anesth Analg 2002;95:930-4
18. Dougherty PM, Aronowski J, Samorajski T, Dafny N. Opiate antinociception is altered by immune modification: the effect of interferon, cyclosporine and radiation-induced immune suppression upon acute and long-term morphine activity. Brain Res 1986;385:401-4
19. Jones BJ, Roberts DJ. A rotarod suitable for quantitative measurements of motor incoordination in naive mice. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1968;259:211
20. Sango K, Yamanaka S, Hoffmann A, Okuda Y, Grinberg A, Westphal H, McDonald MP, Crawley JN, Sandhoff K, Suzuki K, Proia RL. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 1995;11:170-6
21. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 1999;835:18-26
22. Luke DR, Brunner LJ, Vadiei K. Bioavailability assessment of cyclosporine in the rat. Influence of route of administration. Drug Metab Dispos 1990;18:158-62
23. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94:4028-33
24. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502
25. Sato Y, Kobayashi E, Hakamata Y, Kobahashi M, Wainai T, Murayama T, Mishina M, Seo N. Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br J Anaesth 2004;92:859-64
26. Sarton E, Teppema LJ, Olievier C, Nieuwenhuijs D, Matthes HW, Kieffer BL, Dahan A. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001;93:1495-500
27. Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit 1998;20:588-90
28. Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci 2003;92:1739-53
29. Upton RN. Theoretical aspects of P-glycoprotein mediated drug efflux on the distribution volume of anaesthetic-related drugs in the brain. Anaesth Intensive Care 2002;30:183-91
30. Sakata A, Tamai I, Kawazu K, Deguchi Y, Ohnishi T, Saheki A, Tsuji A. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporine A at the blood-brain barrier. Biochem Pharmacol 1994;48:1989-92
31. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000;92:1392-9
32. Scott JA, Wood M, Flood P. The pronociceptive effect of ondansetron in the setting of P-glycoprotein inhibition. Anesth Analg 2006;103:742-6
33. Homayoun H, Babaie A, Gharib B, Etminani A, Khavandgar S, Mani A, Dehpour AR. The involvement of nitric oxide in the antinociception induced by cyclosporine A in mice. Pharmacol Biochem Behav 2002;72:267-72
34. Docherty RJ, Yeats JC, Bevan S, Boddeke HW. Inhibition of calcineurin inhibits the desensitization of capsaicin-evoked currents in cultured dorsal root ganglion neurones from adult rats. Pflugers Arch 1996;431:828-37
35. 2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase. J Biol Chem 2005;280:13424-32